Business

Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth

Financial Post · September 16, 2026 at 8:23 a.m.

MOUNTAIN VIEW, Calif. -- Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027.

The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth

More from Financial Post

Globex Mining Enterprises Inc. Announces Normal Course Issuer Bid

Netflix is paying US$200 million for 2027 Women’s World Cup

ZenaTech Unveils Stacklens™, AI-Powered Smart Safety Glasses Built for Field Technicians and Industrial Workers

OpenAI expects US$70 billion in annualized revenue by end of 2026

More in Business

Globex Mining Enterprises Inc. Announces Normal Course Issuer Bid

Netflix is paying US$200 million for 2027 Women’s World Cup

ZenaTech Unveils Stacklens™, AI-Powered Smart Safety Glasses Built for Field Technicians and Industrial Workers

OpenAI expects US$70 billion in annualized revenue by end of 2026

ADAMnetworks Launches ClickNix, a Free Browser Extension to Stop ClickFix Attacks Before They Ever Reach the User

Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment